Cargando…
Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
SIMPLE SUMMARY: Immune checkpoint blockade (ICB) has become a major treatment for lung cancer. Better understanding of the tumor immune micro-environment (TIME) in non-small cell lung cancer (NSCLC) is urgently needed to better treat it with this type of therapy. In this review, we describe and expl...
Autores principales: | Chi, Alexander, He, Xia, Hou, Lin, Nguyen, Nam P., Zhu, Guangying, Cameron, Robert B., Lee, Jay M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230820/ https://www.ncbi.nlm.nih.gov/pubmed/34208113 http://dx.doi.org/10.3390/cancers13122924 |
Ejemplares similares
-
Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020) -
Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal anti-tumor immunity
por: Choi, Yongbin, et al.
Publicado: (2023) -
Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015) -
Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022) -
Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune “cold” tumors
por: Xiao, Guixiu, et al.
Publicado: (2023)